Breaking News Instant updates and real-time market news.

AGL

AGL Resources

, ARCT

Arcturus Therapeutics

$9.28

-0.32 (-3.33%)

04:55
01/10/18
01/10
04:55
01/10/18
04:55

LifeSci Advisors to hold a conference

LifeSci Advisors Corporate Access Event is being held in San Francisco on January 8-10.

AGL

AGL Resources

ARCT

Arcturus Therapeutics

$9.28

-0.32 (-3.33%)

CRMD

CorMedix

$0.55

-0.0053 (-0.95%)

GLMD

Galmed

$11.77

0.15 (1.29%)

COOL

PolarityTE

$24.98

1.27 (5.36%)

ICAD

iCAD

$3.64

-0.01 (-0.27%)

CYAD

Celyad

$45.20

-1.75 (-3.73%)

HTGM

HTG Molecular

$3.18

-0.22 (-6.47%)

NERV

Minerva

$5.35

-0.2 (-3.60%)

NTEC

Intec Pharma

$6.80

-0.2 (-2.86%)

CTSO

CytoSorbents

$7.40

-0.1 (-1.33%)

RXDX

Ignyta

TXMD

TherapeuticsMD

$6.39

-0.01 (-0.16%)

VBIV

VBI Vaccines

$4.38

-0.01 (-0.23%)

VRML

Vermillion

$1.86

-0.01 (-0.53%)

MRTX

Mirati Therapeutics

$19.05

1.85 (10.76%)

FBIO

Fortress Biotech

$4.08

-0.06 (-1.45%)

FOMX

Foamix

$6.05

-0.13 (-2.10%)

BDSI

BioDelivery Sciences

$2.90

0.05 (1.75%)

  • 10

    Jan

  • 10

    Jan

  • 26

    Feb

  • 29

    May

AGL AGL Resources

ARCT Arcturus Therapeutics
$9.28

-0.32 (-3.33%)

11/29/17
LTCO
11/29/17
INITIATION
Target $22
LTCO
Buy
Arcturus Therapeutics initiated with a Buy at Ladenburg
Ladenburg Thalmann started Arcturus Therapeutics with a Buy rating and $22 price target.
CRMD CorMedix
$0.55

-0.0053 (-0.95%)

09/25/17
HCWC
09/25/17
NO CHANGE
Target $4
HCWC
Buy
CorMedix price target raised to $4 from $3 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for CorMedix to $4 saying meetings with management underscored the market potential for the several medical device-based applications of taurolidine. The analyst reiterates a Buy rating on the shares.
GLMD Galmed
$11.77

0.15 (1.29%)

11/15/17
ROTH
11/15/17
INITIATION
Target $32
ROTH
Buy
Galmed initiated with a Buy at Roth Capital
Roth Capital analyst Yasmeen Rahimi started Galmed with a Buy rating and $32 price target based on his confidence in the clinical success and profitability of the company's lead compound for the treatment of fatty liver disease, medically referred as non-alcoholic hepatosteatosis.
10/06/17
GHSC
10/06/17
INITIATION
Target $19
GHSC
Buy
Galmed initiated with a Buy at Seaport Global
Seaport Global analyst Vernon Bernardino initiated Galmed with a Buy and $19 price target. He thinks the unique activity of Galmed's investigational drug candidate Aramchol in non-alcoholic steatohepatitis differentiates it from other investigational drugs for NASH. Bernardino recommends investors buy the stock, especially on any pullbacks prior to the announcement of top-line results from the ARREST Phase IIb study exepcted in late Q1 2018 or early Q2 2018.
08/08/17
HCWC
08/08/17
NO CHANGE
Target $18
HCWC
Buy
Galmed price target raised to $18 from $12 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Galmed Pharmaceuticals to $18 saying data readouts in the first half of 2018 are set to validate Aramchol in nonalcoholic steatohepatitis. The analyst keeps a Buy rating on the shares.
COOL PolarityTE
$24.98

1.27 (5.36%)

ICAD iCAD
$3.64

-0.01 (-0.27%)

CYAD Celyad
$45.20

-1.75 (-3.73%)

10/09/17
PIPR
10/09/17
NO CHANGE
Target $74
PIPR
Overweight
Celyad price target raised to $74 from $49 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Celyad to $74 after the company last week reported the first ever Morphologic Leukemia-Free Status in an Acute Myeloid Leukemia patient in the first dose cohort of the Phase Ib Think study of CYAD-01 without preconditioning. Fourteen solid and hematologic tumor patients have been dosed in Think and escalation continues with no deaths, Tenthoff tells investors in an intraday research note. He added $258M in value for CYAD-01 in colorectal cancer based on the two patients with stable disease in Think and Celyad's plans to expand enrollment and initiate the Shrink and Link studies. The analyst, who points out his firm has been retained by Celyad as its financial advisor to explore strategic alternatives, reiterates an Overweight rating on the shares.
HTGM HTG Molecular
$3.18

-0.22 (-6.47%)

01/05/18
ADAM
01/05/18
NO CHANGE
Target $5
ADAM
Buy
HTG Molecular price target raised to $5 from $4 at Canaccord
Canaccord analyst Mark Massaro raised his price target on HTG Molecular to $5 after the company announced preliminary fourth quarter results and provided initial full year 2018 revenue guidance.
NERV Minerva
$5.35

-0.2 (-3.60%)

09/01/17
09/01/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DowDuPont (DWDP) initiated with an Outperform at Bernstein. 2. Minerva (NERV) Neurosciences initiated with a Buy at Citi. 3. VMware (VMW) resumed with a Sector Weight at KeyBanc. 4. Provident Financial (PFS) initiated with a Neutral at DA Davidson. 5. Maximus (MMS) initiated with a Neutral at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/01/17
SBSH
09/01/17
INITIATION
Target $11
SBSH
Buy
Minerva Neurosciences initiated with a Buy at Citi
Citi analyst Joel Beatty started Minerva Neurosciences with a Buy rating and $11 price target. The Phase 3 trial for lead agent MIN-101 in negative symptoms of schizophrenia is well positioned for success, Beatty tells investors in a research note. He sees negative symptoms of schizophrenia as an attractive market opportunity because there are no approved drugs for the indication.
03/06/17
JEFF
03/06/17
INITIATION
Target $17
JEFF
Buy
Minerva assumed with a Buy at Jefferies
Jefferies analyst Biren Amin assumed coverage of Minerva with a Buy rating and $17 price target. The analyst believes the company's two candidates MIN-101 and MIN-202 offer upside to the shares.
NTEC Intec Pharma
$6.80

-0.2 (-2.86%)

10/13/17
OPCO
10/13/17
NO CHANGE
Target $15
OPCO
Outperform
Opco more optimistic on Intec Pharma after meeting management
Oppenheimer analyst Jay Olson is "incrementally more optimistic" in his outlook for Intec Pharma after meeting with management. The analyst is "encouraged" by new CEO Jeff Meckler's vision for the Accordion Pill as a platform to unlock significant value for shareholders beyond the current opportunity in Parkinson's disease. Olson maintains an Outperform rating on Intec with a $15 price target.
09/21/17
OPCO
09/21/17
NO CHANGE
Target $15
OPCO
Outperform
Intec Pharma price target raised to $15 from $10 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Intec Pharma to $15 from $10 as he is optimistic about the prospects for its clinical assets which rely on the Accordion Pill platform, namely AP-CD/LD for Parkinson's disease and AP-CBD/THC for chronic pain. The analyst reiterates an Outperform rating on the shares.
CTSO CytoSorbents
$7.40

-0.1 (-1.33%)

07/25/17
AGIS
07/25/17
INITIATION
Target $9
AGIS
Buy
CytoSorbents assumed with a Buy at Aegis
Aegis analyst Evan Wang assumed coverage of CytoSorbents with a Buy rating and $9 price target, as he believes the company's CytoSorb technology for removing excess cytokines from the blood can drive operating profitability by the end of 2018. Wang noted he is "conservatively assuming" initiation of U.S. sales in cardiac applications in 2020.
06/07/17
COWN
06/07/17
INITIATION
Target $7
COWN
Outperform
CytoSorbents initiated with an Outperform at Cowen
Cowen analyst Joshua Jennings initiated CytoSorbents with an Outperform and a $7 price target saying lead product CytoSorb, a filter that removes potentially deadly inflammatory mediators from the blood is now tracking to a $10M+ run rate annually and has several near-term catalysts to boost adoption.
RXDX Ignyta

12/26/17
LTCO
12/26/17
DOWNGRADE
LTCO
Neutral
Ignyta downgraded to Neutral from Buy at Ladenburg
Ladenburg Thalmann analyst Kevin Degeeter downgraded Ignyta (RXDX) to Neutral after the company agreed to be acquired by Roche (RHHBY) for $27 per share.
12/26/17
RHCO
12/26/17
DOWNGRADE
RHCO
Hold
Ignyta downgraded to Hold from Buy at SunTrust
SunTrust downgraded Ignyta (RXDX) to Hold after the company agreed to be acquired by Roche (RHHBY) for $27 per share.
12/26/17
12/26/17
NO CHANGE

On The Fly: Top five analyst actions
Catch up on today's top five analyst rating changes with this list compiled by The Fly: 1. Raymond James analyst Budd Bugatch upgraded Herman Miller (MLHR) to Outperform following newly passed tax reform, as the analyst believes the economic backdrop favors a strong office furniture demand environment and tax reform increases incentives for office furniture purchases. 2. Bugatch also upgraded Knoll (KNL) following the enactment of U.S. tax reform, as he believes its sales force, new product offerings, competitive pricing, and recently announced Muuto acquisition position the company to drive revenue growth as macro conditions improve. 3. Janney Capital analyst Michael Gaugler upgraded Unitil (UTL) to Buy citing the stock's "compelling" valuation. 4. William Blair analyst Tim Lugo late Friday downgraded Agile Therapeutics (AGRX) to Market Perform from Outperform after the company received a complete response letter from the FDA over its hormonal contraceptive patch, Twirla. While the issues raised by the FDA may be addressable, he has concerns regarding management's execution of the company's lead product. 5. Ignyta (RXDX) was downgraded to Hold at SunTrust and to Neutral at Ladenburg after the company agreed to be acquired by Roche (RHHBY) for $27 per share. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/28/17
CANT
12/28/17
DOWNGRADE
Target $27
CANT
Neutral
Ignyta downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Mara Goldstein downgraded Ignyta (RXDX) to Neutral saying a competing takeover bid to Roche's (RHHBY) is unlikely. The analyst raised her price target for the shares to $27 from $23.
TXMD TherapeuticsMD
$6.39

-0.01 (-0.16%)

12/20/17
DBAB
12/20/17
NO CHANGE
Target $9
DBAB
Buy
Deutsche keeps Buy rating, $9 target on TherapeuticsMD
Deutsche Bank analyst Esther Rajavelu says that as expected, TherapeuticsMD announced the FDA's acceptance of the resubmitted TX-004 new drug application with an action date of May 29, 2018, for the treatment of moderate to severe dyspareunia in menopausal women. The analyst continues to anticipate approval of both TX-004 and TX-001 in 2018. She believes the company in the company weeks will announce the TX-001 new drug application submission and a $150M of term loan financing. Rajavelu keeps a Buy rating on the shares with a $9 price target.
12/20/17
CANT
12/20/17
NO CHANGE
Target $28
CANT
Overweight
TherapeuticsMD may seek another raise capital, says Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner says the FDA designating TherapeuticsMD's TX-004 resubmission as class 2 tacks six months onto the review. TX-004 will likely be launched at least a year after it could have been with a first cycle approval, Tanner tells investors in a research note titled "So That's What The Stock Weakness Was About: FDA Designates Resubmission Class 2." The analyst would not be surprised if last night's news gives bears "something of a sigh of relief." He also believes "yet another financing could be in the cards" for TherapeuticsMD. As such, the analyst lowered his price target for the shares to $28 from $31. Tanner keeps an Overweight rating on the stock.
12/21/17
OPCO
12/21/17
NO CHANGE
Target $10
OPCO
Outperform
FDA designation of TherapeuticsMD TX-004HR as Class 2 surprising, says Oppenheimer
Oppenheimer analyst Jay Olson notes that the FDA has accepted TherapeuticsMD's TX-004HR NDA as a class 2 resubmission which requires a 6-month review resulting in a May 29, 2018 PDUFA. While the analyst is pleased with FDA's acceptance of the resubmission, he is surprised at the agency's designation as a class 2, which was apparently triggered by the additional endometrial safety data. This data was submitted several months ago, giving the FDA a significant head start to review it, he contends. Olson reiterates an Outperform rating and $10 price target on the shares.
12/29/17
CANT
12/29/17
NO CHANGE
Target $28
CANT
Overweight
TherapeuticsMD's TX-001 could be 'far bigger' than TX-004, says Cantor
Cantor Fitzgerald analyst William Tanner reiterates his belief that TherapeuticsMD's TX-001 could be a "far-bigger" drug than the company's TX-004. Consistent with previous guidance, TherapeuticsMD filed yesterday the new drug application for TX-001, the estrogen plus progesterone hormone replacement therapy for treating vasomotor symptoms associated with menopause in women, Tanner tells investors in a research note. If approved, TX-001 could enter a vasomotor symptoms market "characterized by the absence of FDA-approved therapies," the analyst contends. He believes investors may be overlooking TX-001 "with all the fireworks over TX-004 in the past six months." Tanner reiterates an Overweight rating on TherapeuticsMD with a $28 price target. The stock in premarket trading is up 4% to $6.19.
VBIV VBI Vaccines
$4.38

-0.01 (-0.23%)

11/01/17
11/01/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Gildan Activewear (GIL) initiated with a Neutral at Macquarie. 2. Proofpoint (PFPT) initiated with a Perform at Oppenheimer. 3. LendingClub (LC) initiated with a Buy at Needham. 4. Melco Resorts & Entertainment (MLCO) initiated with a Buy at Roth Capital. 5. VBI Vaccines (VBIV) initiated with a Buy at Canaccord. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/15/17
BMOC
11/15/17
INITIATION
Target $11
BMOC
Outperform
VBI Vaccines initiated with an Outperform at BMO Capital
BMO Capital analyst Do Kim started VBI Vaccines (VBI) with an Outperform rating and $11 price target. The analyst believes the company's Phase III hepatitis B virus vaccine, Sci-B-Vac, will be preferred over Dynavax's (DVAX) Heplisav-B in the premium-priced HBV vaccine market.
11/01/17
ADAM
11/01/17
INITIATION
Target $10
ADAM
Buy
VBI Vaccines initiated with a Buy at Canaccord
Canaccord analyst John Newman initiated VBI Vaccines with a Buy rating as he views its vaccine for hepatitis B as potentially the best-in-class based on head to head data with competitors. He sees the company with a commercial edge and conservatively sees $370M worldwide sales potential. The analyst also likes the company's pipeline, which represents additional upside value. Newman has a $10 price target on VBI Vaccines shares.
VRML Vermillion
$1.86

-0.01 (-0.53%)

09/25/17
ADAM
09/25/17
NO CHANGE
ADAM
Genomic Health, Vermillion among 'few winners' after PAMA news, says Canaccord
After the CMS released the proposed 2018 draft Medicare reimbursement rates for clinical lab tests under the Protecting Access to Medicare Act, or PAMA, which marks a major overhaul of Medicare reimbursement for tests, Canaccord analyst Mark Massaro said the cuts were greater than he expected. He identifies the "losers" after the news as LabCorp (LH), Quest Diagnostics (DGX) and GenMark (GNMK) while he sees Genomic Health (GHDX), VeraCyte (VCYT) and Vermillion (VRML) as among the "few winners."
08/30/17
ADAM
08/30/17
NO CHANGE
Target $2
ADAM
Buy
Vermillion could see material increase in 2018 reimbursement, says Canaccord
Canaccord analyst Mark Massaro noted Vermillion reported a shortfall in volumes in Q2 and guided to lower Q3 volumes due to a loss of a larger legacy customer. The analyst said the company is feeling good about being a winner from PAMA and, if implemented as planned, could see a material bump higher in reimbursement in 2018. Massaro maintained his Buy rating and lowered his price target to $1.75 from $2.50 on Vermillion shares.
MRTX Mirati Therapeutics
$19.05

1.85 (10.76%)

01/09/18
HCWC
01/09/18
NO CHANGE
Target $21
HCWC
Buy
Mirati Therapeutics price target raised to $21 from $17 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for Mirati Therapeutics (MRTX) to $21 after the company entered into an exclusive licensing agreement with BeiGene (BGNE) for the development, manufacturing and commercialization of sitravatinib. The analyst keeps a Buy rating on the shares after meeting with management.
11/14/17
HCWC
11/14/17
NO CHANGE
Target $17
HCWC
Buy
Mirati price target lowered to $17 on glesatinib news at H.C. Wainwright
H.C. Wainwright analyst Edward White lowered his price target on Mirati Therapeutics to $17 from $20 after the company announced that it is putting development of its lead pipeline candidate, glesatinib, on hold and reallocating resources to accelerate development of its sitravatinib and KRAS programs. The analyst, who notes that Mirati's products are in early development, maintains a Buy rating on the stock.
12/21/17
COWN
12/21/17
INITIATION
COWN
Outperform
Mirati Therapeutics initiated with an Outperform at Cowen
Cowen analyst Chris Shibutani started Mirati Therapeutics with an Outperform rating and no price target. The analyst sees mid-2018 data readouts for Sitravatinib as supporting continued stock outperformance. He notes his proprietary expert surveys "support enthusiasm" for Sitravatinib to play a role in the "increasingly important" post-checkpoint inhibitors setting.
11/14/17
11/14/17
UPGRADE
Target $20

Outperform
Mirati Therapeutics upgraded to Outperform at Leerink
As previously reported, Leerink analyst Michael Schmidt upgraded Mirati Therapeutics to Outperform from Market Perform after the company announced that it is reprioritizing its pipeline programs. Investment in lead product candidate glesatinib is being "de-prioritized," while freed-up resources are being reallocated to the significantly more promising sitravatinib program as well as preclinical efforts to target KRas, he adds. Schmidt thinks this news comes only as a small surprise to investors and is actually positive. The analyst also raised his price target on the shares to $20 from $15.
FBIO Fortress Biotech
$4.08

-0.06 (-1.45%)

03/22/17
JMPS
03/22/17
INITIATION
JMPS
Outperform
Fortress Biotech initiated at JMP Securities
As noted earlier, JMP Securities started coverage of Fortress Biotech with an Outperform rating. Analyst Michael King is upbeat on the track record of the company's management and its ability to acquire drugs that will generate "substantial and diverse revenue streams." Target $11.
07/11/17
RODM
07/11/17
INITIATION
Target $11
RODM
Buy
Fortress Biotech initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Joseph Pantginis started Fortress Biotech with a Buy rating and $11 price target. The analyst says the company and its nine subsidiaries are developing a "diverse set of programs across a broad range of therapeutic areas."
03/22/17
JMPS
03/22/17
INITIATION
Target $11
JMPS
Outperform
Fortress Biotech initiated with an Outperform at JMP Securities
JMP Securities analyst Michael King initiated Fortress Biotech with an Outperform and an $11 price target.
FOMX Foamix
$6.05

-0.13 (-2.10%)

01/04/18
COWN
01/04/18
NO CHANGE
Target $30
COWN
Outperform
Foamix valuation doesn't 'nearly reflect' FMX101, 103 potential, says Cowen
Cowen analyst Ken Cacciatore said that a one year open label extension study has confirmed the safety profile of FMX101, which has efficacy data coming in mid-2018. The company should also report data on a study of FMX103 in rosacea in the middle of the year, according to Cacciatore, who contends that the valuation of Foamix shares "does not nearly reflect the potential of these assets." He maintains an Outperform rating and $30 price target on Foamix.
08/24/17
HCWC
08/24/17
INITIATION
Target $12
HCWC
Buy
Foamix initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju initiated Foamix with a Buy and a $12 price target saying shares were excessively punished when the company reported data in March from the second of two pivotal trials already completed with FMX101. He believes that both trials were indicative of clinical activity and that the company is justified in conducting a third study. Selvaraju notes that this confirmatory trial is using a similar design but is enrolling 1,500 subjects, in contrast, the two completed pivotal trials each enrolled less than500 patients. Thus, he thinks the market is not adequately valuing Foamix's chances of success, and consider shares well positioned for a rebound to double-digit levels upon receipt of positive top-line data from the third FMX101 trial.
12/05/17
GUGG
12/05/17
INITIATION
Target $8
GUGG
Buy
Foamix initiated with a Buy at Guggenheim
Guggenheim analyst Rohit Vanjani initiated Revance with a Buy and $8 price target.
08/24/17
08/24/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zimmer Biomet (ZBH) initiated with a Buy at Gabelli. 2. Foamix (FOMX) initiated with a Buy at H.C. Wainwright. 3. Netlist (NLST) initiated with a Buy at Roth Capital. 4. Flexion (FLXN) initiated with an Outperform at Northland. 5. USA Technologies (USAT) initiated with an Outperform at William Blair. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BDSI BioDelivery Sciences
$2.90

0.05 (1.75%)

08/14/17
CANT
08/14/17
INITIATION
CANT
Overweight
BioDelivery Sciences coverage assumed with an Overweight at Cantor
Cantor analyst Brandon Folkes assumed coverage of BioDelivery Sciences with a $4.50 price target and an Overweight rating. The analyst thinks that two of the company's products could be boosted by the FDA's efforts to promote the use of pain treatments that are less likely than opioids to be abused and become addictive .
07/24/17
JANY
07/24/17
NO CHANGE
Target $4
JANY
Buy
BioDelivery Sciences price target raised to $4 from $3 at Janney Capital
Janney Capital analyst Ken Trbovich sees multiple reasons to expect BioDelivery Sciences' Belbuca growth above current levels, including the continued maturing of its newer sales people, the opportunity to secure Medicare coverage contracts and Endo's (ENDP) recent decision to remove Opana ER from the market. He raised his fair value estimate on BioDelivery to $4 from $3 and keeps a Buy rating on the stock.
11/27/17
HCWC
11/27/17
NO CHANGE
HCWC
BioDelivery Sciences' Belbuca continues to trend up, says H.C. Wainwright
H.C. Wainwright analyst Oren Livnat noted that BioDelivery Sciences' pain drug Belbuca continues a steady upward trajectory, and believes that if lobbying efforts and initiatives addressing the opioid epidemic "result in more substantial changes to managed care access, CDC guidelines, or even FDA opioid labelling, there could be upside to long-term peak" for Belbuca sales. Livnat reiterated a Buy rating and $5 price target on BioDelivery Sciences shares.
08/14/17
08/14/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Brighthouse Financial (BHF) initiated with an Equal Weight at Morgan Stanley. 2. Kala Pharmaceuticals (KALA) was initiated with a Buy at BofA/Merrill, an Outperform at Wedbush, Wells Fargo, and Wedbush, as well as an Overweight at JPMorgan. 3. BioDelivery Sciences (BDSI) coverage assumed with an Overweight at Cantor. 4. Calyxt (CLXT) was initiated with an Outperform at Wells Fargo and a Buy at Jefferies. 5. TPG RE Finance (TRTX) was initiated with a Buy at BofA/Merrill, and a Neutral at JPMorgan and Citi. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

02:40
01/18/18
01/18
02:40
01/18/18
02:40
General news
FX Update: The dollar edged out fresh recovery highs »

FX Update: The dollar…

MS

Morgan Stanley

$55.35

0.75 (1.37%)

, BK

BNY Mellon

$57.89

0.35 (0.61%)

20:25
01/17/18
01/17
20:25
01/17/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MS

Morgan Stanley

$55.35

0.75 (1.37%)

BK

BNY Mellon

$57.89

0.35 (0.61%)

BBT

BB&T

$53.28

0.2 (0.38%)

PPG

PPG

$114.50

-2.14 (-1.83%)

MTB

M&T Bank

$179.21

1.43 (0.80%)

KEY

KeyCorp

$21.26

-0.06 (-0.28%)

JBHT

J.B. Hunt

$120.65

0.01 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 08

    Mar

  • 10

    May

ARNA

Arena Pharmaceuticals

$34.36

0.48 (1.42%)

20:24
01/17/18
01/17
20:24
01/17/18
20:24
Initiation
Arena Pharmaceuticals initiated at Credit Suisse »

Arena Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROSE

Rosehill Resources

$7.96

0.01 (0.13%)

20:12
01/17/18
01/17
20:12
01/17/18
20:12
Initiation
Rosehill Resources initiated at Northland »

Rosehill Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$54.02

0.48 (0.90%)

20:10
01/17/18
01/17
20:10
01/17/18
20:10
Initiation
Hess Corp. initiated at Macquarie »

Hess Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

OXY

Occidental Petroleum

$75.86

0.59 (0.78%)

20:10
01/17/18
01/17
20:10
01/17/18
20:10
Initiation
Occidental Petroleum initiated at Macquarie »

Occidental Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

JUNO

Juno Therapeutics

$69.25

23.65 (51.86%)

19:53
01/17/18
01/17
19:53
01/17/18
19:53
Downgrade
Juno Therapeutics rating change at Citi »

Juno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WP

Worldpay

$77.89

-0.37 (-0.47%)

19:52
01/17/18
01/17
19:52
01/17/18
19:52
Upgrade
Worldpay rating change at BMO Capital »

Worldpay upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRAC

Keane Group

$18.51

0.63 (3.52%)

19:52
01/17/18
01/17
19:52
01/17/18
19:52
Syndicate
Keane Group 13.3M share Secondary priced at $18.25 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

INTC

Intel

$44.39

1.25 (2.90%)

19:24
01/17/18
01/17
19:24
01/17/18
19:24
Hot Stocks
Intel says issued firmware updates for 90% of CPUs in past vie years »

Intel said it has made…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 24

    Jan

  • 25

    Jan

TOSBF

Toshiba, also use TOSYY

, TOSYY

Toshiba, also use TOSBF

$16.95

-0.01 (-0.06%)

19:11
01/17/18
01/17
19:11
01/17/18
19:11
Periodicals
Toshiba's Westinghouse to forgo bankruptcy, Reuters reports »

Westinghouse Electric…

TOSBF

Toshiba, also use TOSYY

TOSYY

Toshiba, also use TOSBF

$16.95

-0.01 (-0.06%)

BAM

Brookfield

$43.10

0.42 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDS.A

Royal Dutch Shell

$70.20

0.22 (0.31%)

, RDS.B

Royal Dutch Shell

$72.34

0.35 (0.49%)

19:02
01/17/18
01/17
19:02
01/17/18
19:02
Periodicals
Shell, BP each agree to purchase Libyan oil, Bloomberg reports »

Royal Dutch Shell (RDS.A)…

RDS.A

Royal Dutch Shell

$70.20

0.22 (0.31%)

RDS.B

Royal Dutch Shell

$72.34

0.35 (0.49%)

BP

BP

$42.88

0.42 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AAPL

Apple

$179.10

2.91 (1.65%)

18:31
01/17/18
01/17
18:31
01/17/18
18:31
Hot Stocks
Trump says Apple investments 'huge win for American workers' »

President Donald Trump…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

MPVD

Mountain Province Diamonds

$2.83

0.075 (2.73%)

18:22
01/17/18
01/17
18:22
01/17/18
18:22
Hot Stocks
Mountain Province Diamonds provides update on Gahcho Kue Mine exploration »

Mountain Province…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAC

Walter Investment

$0.76

0.0347 (4.81%)

18:17
01/17/18
01/17
18:17
01/17/18
18:17
Hot Stocks
Walter Investment prepackaged Chapter 11 plan approved by court »

Walter Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TM

Toyota

$140.72

2.75 (1.99%)

, KBSTY

Kobe Steel

18:10
01/17/18
01/17
18:10
01/17/18
18:10
Periodicals
Toyota not affected by Kobe Steel false data scandal, Nikkei reports »

Toyota (TM) said there…

TM

Toyota

$140.72

2.75 (1.99%)

KBSTY

Kobe Steel

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBOE

Cboe Global Markets

$131.52

0.73 (0.56%)

, BTC

Bitcoin

17:47
01/17/18
01/17
17:47
01/17/18
17:47
Hot Stocks
Cboe conducts first settlement of Cboe bitcoin futures »

Cboe Global Markets…

CBOE

Cboe Global Markets

$131.52

0.73 (0.56%)

BTC

Bitcoin

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Feb

GWRE

Guidewire

$75.64

0.19 (0.25%)

17:46
01/17/18
01/17
17:46
01/17/18
17:46
Hot Stocks
Guidewire director sells 6,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.10

2.91 (1.65%)

17:40
01/17/18
01/17
17:40
01/17/18
17:40
Recommendations
Apple analyst commentary at Piper Jaffray »

Apple cash repatriation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

OBE

Obsidian Energy

$1.21

-0.03 (-2.42%)

17:36
01/17/18
01/17
17:36
01/17/18
17:36
Hot Stocks
Breaking Hot Stocks news story on Obsidian Energy »

FrontFour reports 5.7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SN

Sanchez Energy

$5.81

0.16 (2.83%)

17:33
01/17/18
01/17
17:33
01/17/18
17:33
Hot Stocks
Breaking Hot Stocks news story on Sanchez Energy »

Sanchez Energy sees Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

NTDOY

Nintendo

$51.53

1.55 (3.10%)

17:32
01/17/18
01/17
17:32
01/17/18
17:32
Hot Stocks
Nintendo announces Nintendo Labo accessories for Switch consoles »

Nintendo introduced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

PTC

PTC

$66.70

1.41 (2.16%)

, ESIO

Electro Scientific

$22.01

1.91 (9.50%)

17:28
01/17/18
01/17
17:28
01/17/18
17:28
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: PTC…

PTC

PTC

$66.70

1.41 (2.16%)

ESIO

Electro Scientific

$22.01

1.91 (9.50%)

NEOT

Neothetics

$1.92

0.0793 (4.31%)

PLXS

Plexus

$64.36

0.59 (0.93%)

AA

Alcoa

$56.99

0.75 (1.33%)

SLM

Sallie Mae

$11.49

0.02 (0.17%)

ARWR

Arrowhead

$5.72

0.12 (2.14%)

PRTK

Paratek Pharmaceuticals

$17.68

-0.075 (-0.42%)

IIPR

Innovative Industrial Properties

$31.30

-2.49 (-7.37%)

ECC

Eagle Point Credit

$19.13

-0.39 (-2.00%)

AGIO

Agios Pharmaceuticals

$70.33

1.53 (2.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 18

    Jan

  • 18

    Jan

  • 07

    Feb

  • 26

    Feb

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 19

    Jan

BTU

Peabody Energy

$40.00

0.42 (1.06%)

17:17
01/17/18
01/17
17:17
01/17/18
17:17
Hot Stocks
Breaking Hot Stocks news story on Peabody Energy »

Discovery Capital reduces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

MLNX

Mellanox

$64.30

-0.45 (-0.69%)

17:12
01/17/18
01/17
17:12
01/17/18
17:12
Hot Stocks
Starboard to nominate nine directors for election at Mellanox »

Starboard Value, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.